Key result
SR protein kinases (SRPK1, CLK1, and AKT2) phosphorylated S638 and S640 in the RSRSP stretch and regulated RBM20 target gene splicing, highlighting them as potential therapeutic targets.
Why the study?
The identity of the kinase responsible for phosphorylating the RSRSP stretch in RBM20, and the functional role of this phosphorylation, remained unknown.
SR protein kinases SRPK1, CLK1, and AKT2 phosphorylate the RSRSP stretch in RBM20 and regulate cardiomyopathy-relevant gene splicing, suggesting they may be potential therapeutic targets for RBM20 cardiomyopathy.
Answers are grounded in this paper and cite their sources.
May nominate SRPK1/CLK1/AKT2 as targets in RBM20 cardiomyopathy; leaves open human translation.
(1) Background: RNA binding motif 20 (RBM20) regulates mRNA splicing specifically in muscle tissues. Missense mutations in the arginine/serine (RS) domain of RBM20 lead to abnormal gene splicing and have been linked to severe dilated cardiomyopathy (DCM) in human patients and animal models. Interestingly, many of the reported DCM-linked missense mutations in RBM20 are in a highly conserved RSRSP stretch within the RS domain. Recently, it was found that the two Ser residues within this stretch are constitutively phosphorylated, yet the identity of the kinase(s) responsible for phosphorylating these residues, as well as the function of RSRSP phosphorylation, remains unknown. (2) Methods: The ability of three known SR protein kinases (SRPK1, CLK1, and AKT2) to phosphorylate the RBM20 RSRSP stretch and regulate target gene splicing was evaluated by using both in vitro and in vivo approaches. (3) Results: We found that all three kinases phosphorylated S638 and S640 in the RSRSP stretch and regulated RBM20 target gene splicing. While SRPK1 and CLK1 were both capable of directly phosphorylating the RS domain in RBM20, whether AKT2-mediated control of the RS domain phosphorylation is direct or indirect could not be determined. (4) Conclusions: Our results indicate that SR protein kinases regulate the splicing of a cardiomyopathy-relevant gene by modulating phosphorylation of the RSRSP stretch in RBM20. These findings suggest that SR protein kinases may be potential targets for the treatment of RBM20 cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2022) studied Dilated cardiomyopathy (DCM). SR protein kinases (SRPK1, CLK1, and AKT2) was evaluated on Phosphorylation of the RBM20 RSRSP stretch and regulation of target gene splicing. SR protein kinases (SRPK1, CLK1, and AKT2) phosphorylated S638 and S640 in the RSRSP stretch and regulated RBM20 target gene splicing, highlighting them as potential therapeutic targets.
Synapse has enriched 10 related papers. Consider them for comparative context: